-Reuters Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumour. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai's biggest cancer hospital. "What is a generic drug?" shrugs Nissar, who has travelled over 1,500 kms (900 miles) from his home in the hope of treatment. "I have borrowed money from friends and relatives...
More »SEARCH RESULT
A life saver-Shamnad Basheer
Compulsory licence can go a long way to ensure access to cheaper drugs In a momentous development, the Indian patent office issued the ever-compulsory licence in a highly contentious pharmaceutical patent case. The decision is a thumping victory for several patients and health activists who have been fighting what can only be labelled as highly inequitable pricing strategies by multinational drug firms for the past several decades. In August 2011, Natco, an...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory Licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »Road to cheaper drugs by Rupali Mukherjee
The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory Licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases. More generic companies could invoke the compulsory Licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...
More »Natco Pharma bags licence to sell Bayer's cancer drug Nexavar
-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory Licensing provision. The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...
More »